P374. Probiotics can extend remission of ulcerative colitis
O. Solovyeva, North-Western state medical university named after I.I. Mechnikov, Therapy and clinical pharmacology, Saint-Petersburg, Russian Federation
Inflammatory bowel disease is one of the most impotent problems of gastroenterology. Modern therapy not always allows to reach remissions and to keep its long time. It is known that infringements in gut microflora are capable to support inflammatory processes at ulcerative colitis.
The purpose of our research was to estimate influence of probiotic therapy on a current ulcerative colitis.
Patients with active moderate ulcerative colitis (47) were randomized on 2 groups: patients of the first group received standard therapy by mesalazin in a dose 3 g/day, patients of the second group received therapy by mesalazin in a dose 3 g/day in a combination with probiotic containing Enterococcus faecium L-3 in a dose 3 dragees 3 times a day in a current of 1 month.
Patients were exposed clinical and endoscopic examination. Clinical activity index (CAI) and endoscopic activity index (EAI) of ulcerative colitis were calculated before treatment, through 2 and in 6 months from an initiation of treatment. Microbiological research was carried out for revealing of degree of infringements in intestinal microflora.
Prior to the beginning of treatment both groups of patients were statistically comparable. Average CAI in the first group of patients was 10.4±1.4 points, average EAI - 7.0±1.1 points. In the second group of patients these indicators were 10.0±1.2 and 7.2±1.0 points accordingly. In 2 months from an initiation of treatment in both groups it was observed authentic (p < 0.005) decrease CAI (1 group - 3.7±0.3 points, 2 group - 3.7±0.2 points) and EAI (p < 0.005) (1 group - 2.7±0.2 points, 2 group - 2.8±0.3 points). At control research in 6 months average CAI in the first group of patients was 6.7±1.3 points against 4.5±1.5 points in the group receiving probiotic containing Enterococcus faecium L-3 (p < 0.01), and EAI was 5.0±1.6 against 3.2±1.0 points (p < 0.01) accordingly.
The therapy combination mesalazin with probiotic therapy allows to reach clinical and endoscopic remissions of ulcerative colitis. Use of probiotic in treatment ulcerative colitis allows to support long time disease remission.